| |
| | Patent 6,896,898 |
 | | Aconitine alkaloids may be delivered by themselves, or in combination with other elements, such as additional analgesics, other drugs, or positive health promoting substances. |
 | | In one aspect, the aconitine alkaloid may be a member selected from the group consisting of lappaconitine, N-deacetyl-lappaconitine, songtiening, bulleyaconitine A, 3-acetylaconitin, isolappaconitine, deoxylappaconitine, neofinaconitine, ranaconitine, N-deacetylranaconitine, finaconitine, N-deacetylfinaconitine, mesaconitine, jesaconitine, and salts, analogs, derivatives, prodrugs, and mixtures thereof. |
 | | In the case of the adhesive matrix patch, an amount of an aconitine alkaloid sufficient to produce the desired therapeutic blood plasma level is dissolved or suspended in a polymeric phase or carrier. |
| www.pharmcast.com /Patents100/Yr2005/May2005/052405/6896898_Transdermal052405.htm (5424 words) |
|